Back to map

Population: 4,300,000

Largest cities: Zagreb (capital), Split, Rijeka

Approval Process

Apart from a few small deviations, Croatian legislation has already incorporated EU directives.


  • realistic start-up time: 5 months
Recruitment Potential

There are over 100 new trials registered in Croatia each year. Croatia has gained reputation for high rates of evaluable subject recruitment, with high patient compliance. This is especially evident in oncology, rare disease and pediatric clinical trials, which have become increasingly difficult to conduct in Western countries due to considerable patient reluctance.

Croatia is ranked as the 3rd country in the world with regard to lung cancer incidence.

Estimated deaths per 100,000 population by cause (higher than world/European average):

Diseases Croatia World Average Europe Average
Cardiovascular Disease 618.31 270.13 490.54
Malignant Neoplasms 300.83 112.06 208.74
Gastrointestinal Diseases 56.09 33.73 45.75
Neuropsychiatric Diseases 36.38 21.46 35.89
Diabetes Mellitus 30.18 24.94 20.90
Genitourinary Diseases 18.63 15.91 14.88
Unintentional Injuries 49.22 46.22 44.04

Data from World Health Organization

Investigators and Sites

Health institutions are adequately equipped with the latest scientific and medical instruments and have highly qualified, experienced staff.

Almost 50% of sites are located in Zagreb, the capital of Croatia. The centerpiece of the capital’s health system is the University Hospital. This system is well supported throughout Croatia by a network of both regional and city hospitals, including three medical schools in Split, Rijeka and Osijek.

The vast majority of investigators from these institutions has extensive experience in leading clinical research as part of a global research programs and are fluent in English.